Eupraxia Pharmaceuticals (EPRX) Interest Expenses (2022 - 2025)
Eupraxia Pharmaceuticals (EPRX) posted quarterly Interest Expenses of $18365.0 for Q4 2025, down 98.48% year-over-year from $1.2 million in Q4 2024, and down 98.48% quarter-over-quarter from $1.2 million in Q4 2024.
Eupraxia Pharmaceuticals (EPRX) Interest Expenses (2022 - 2025) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has reported Interest Expenses for 4 consecutive years, with $18365.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Interest Expenses fell 98.48% year-over-year to $18365.0; the TTM figure through Dec 2025 stood at $18365.0 (down 96.96% YoY), while the FY2025 annual figure was $43.4 million, up 38.45% from the prior year.
- Interest Expenses retreated to $18365.0 in Q4 2025 per EPRX's latest filing, from $1.2 million in the prior quarter.
- Across five years, Interest Expenses topped out at $17.1 million in Q4 2022 and bottomed at -$321140.0 in Q1 2024.
- Historically, Interest Expenses has averaged $1.9 million across 4 years, with a median of -$141148.0 in 2024.
- Annual changes were most pronounced in 2024 — Interest Expenses jumped 99.86% — and 2025, when it plunged 98.48%.
- Eupraxia Pharmaceuticals' Interest Expenses stood at $17.1 million in 2022, then plunged by 87.85% to $2.1 million in 2023, then sank by 42.08% to $1.2 million in 2024, then slumped by 98.48% to $18365.0 in 2025.
- Business Quant data shows EPRX's Interest Expenses at $18365.0 in Q4 2025, $1.2 million in Q4 2024, and -$451.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Eupraxia Pharmaceuticals | 381.11 Mn | 379.51 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 18,365.00 |
| Dec 31, 2025 | 18,365.00 |
| Dec 31, 2024 | 1.21 Mn |
| Dec 31, 2024 | 1.21 Mn |
| Sep 30, 2024 | -451.00 |
| Sep 30, 2024 | -451.00 |
| Jun 30, 2024 | -281,845.00 |
| Jun 30, 2024 | -281,845.00 |
| Mar 31, 2024 | -321,140.00 |
| Mar 31, 2024 | -321,140.00 |
| Dec 31, 2023 | 2.08 Mn |
| Dec 31, 2023 | 2.08 Mn |
| Sep 30, 2023 | -320,466.00 |
| Sep 30, 2023 | -320,466.00 |
| Jun 30, 2023 | -301,770.00 |
| Jun 30, 2023 | -301,770.00 |
| Mar 31, 2023 | -291,477.00 |
| Mar 31, 2023 | -291,477.00 |
| Dec 31, 2022 | 17.15 Mn |
| Dec 31, 2022 | 17.15 Mn |